Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

High Incidence of Active Tuberculosis in Asylum Seekers from Eritrea and Somalia in the First 5 Years after Arrival in the Netherlands.

van den Boogaard J, Slump E, Schimmel HJ, van der Hoek W, van den Hof S, de Vries G.

Emerg Infect Dis. 2020 Apr;26(4):675-681. doi: 10.3201/eid2604.190123.

2.

Strategies to reach and motivate migrant communities at high risk for TB to participate in a latent tuberculosis infection screening program: a community-engaged, mixed methods study among Eritreans.

Spruijt I, Haile DT, Erkens C, van den Hof S, Goosen S, Ten Kate A, Teshome H, Karels M, Koenders M, Suurmond J.

BMC Public Health. 2020 Mar 12;20(1):315. doi: 10.1186/s12889-020-8390-9.

3.

Tuberculin skin test reaction depends on type of purified protein derivative: implications for cut-off values.

Mulder C, Erkens C, Kouw P, Huisman E, Toumanian S, van den Hof S.

Int J Tuberc Lung Dis. 2019 Dec 1;23(12):1327-1334. doi: 10.5588/ijtld.18.0838.

PMID:
31931917
4.

Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.

Xia H, van den Hof S, Cobelens F, Zhou Y, Zhao B, Wang S, Zhao Y.

BMC Infect Dis. 2020 Jan 7;20(1):19. doi: 10.1186/s12879-020-4758-9.

5.

Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences.

Tiemersma E, van den Hof S, Dravniece G, Wares F, Molla Y, Permata Y, Lukitosari E, Quelapio M, Aung ST, Aung KM, Thuy HT, Hoa VD, Sulaimanova M, Sagyndikova S, Makhmudova M, Soliev A, Kimerling M.

Eur Respir Rev. 2019 Oct 11;28(153). pii: 180115. doi: 10.1183/16000617.0115-2018. Print 2019 Sep 30. Review.

6.

Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.

Spruijt I, Tesfay Haile D, Suurmond J, van den Hof S, Koenders M, Kouw P, van Noort N, Toumanian S, Cobelens F, Goosen S, Erkens C.

Eur Respir J. 2019 Nov 28;54(5). pii: 1900861. doi: 10.1183/13993003.00861-2019. Print 2019 Nov.

PMID:
31537698
7.

Hotspots for transmission of extensively drug-resistant tuberculosis.

van den Hof S.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):643-644. doi: 10.5588/ijtld.19.0272. No abstract available.

PMID:
31315695
8.

Implementation of latent tuberculosis infection screening and treatment among newly arriving immigrants in the Netherlands: A mixed methods pilot evaluation.

Spruijt I, Erkens C, Suurmond J, Huisman E, Koenders M, Kouw P, Toumanian S, Cobelens F, van den Hof S.

PLoS One. 2019 Jul 1;14(7):e0219252. doi: 10.1371/journal.pone.0219252. eCollection 2019.

9.

Added Value of Comprehensive Program to Provide Universal Access to Care for Sputum Smear-Negative Drug-Resistant Tuberculosis, China.

Huang F, van den Hof S, Qu Y, Li Y, Zhang H, Wang L, Sun M, Lu W, Hou S, Zhang T, Huan S, Chin DP, Cobelens F.

Emerg Infect Dis. 2019 Jul;25(7):1289-1296. doi: 10.3201/eid2507.181417.

10.

Successfully Engaging Private Providers to Improve Diagnosis, Notification, and Treatment of TB and Drug-Resistant TB: The EQUIP Public-Private Model in Chennai, India.

Ananthakrishnan R, Richardson MD, van den Hof S, Rangaswamy R, Thiagesan R, Auguesteen S, Kamp N.

Glob Health Sci Pract. 2019 Mar 29;7(1):41-53. doi: 10.9745/GHSP-D-18-00318. Print 2019 Mar 22.

11.

Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.

Makhmudova M, Maxsumova Z, Rajabzoda A, Makhmadov A, van den Hof S, Mirtskhulava V.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):331-336. doi: 10.5588/ijtld.18.0311.

PMID:
30871664
12.

Patient support for tuberculosis patients in low-incidence countries: A systematic review.

van de Berg S, Jansen-Aaldring N, de Vries G, van den Hof S.

PLoS One. 2018 Oct 10;13(10):e0205433. doi: 10.1371/journal.pone.0205433. eCollection 2018.

13.

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.

Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, Alffenaar JW.

Br J Clin Pharmacol. 2018 Dec;84(12):2747-2760. doi: 10.1111/bcp.13722. Epub 2018 Oct 3.

14.

Patient support during treatment for active tuberculosis and for latent tuberculosis infection: Policies and practices in European low-incidence countries.

Jansen-Aaldring N, van de Berg S, van den Hof S.

J Adv Nurs. 2018 Dec;74(12):2755-2765. doi: 10.1111/jan.13784. Epub 2018 Aug 2.

PMID:
29964334
15.

Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.

de Vries G, van den Hof S, Op de Coul E, van Crevel R.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702671. doi: 10.1183/13993003.02671-2017. Print 2018 Mar. No abstract available.

16.

Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.

Arnoldussen M, Schimmel H, Op de Coul E, van den Hof S, de Vries G.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701257. doi: 10.1183/13993003.01257-2017. Print 2017 Nov. No abstract available.

17.

Evaluation of tuberculosis screening of immigrants in the Netherlands.

van de Berg S, Erkens C, van Rest J, van den Hof S, Kamphorst M, Keizer S, de Vries G.

Eur Respir J. 2017 Oct 12;50(4). pii: 1700977. doi: 10.1183/13993003.00977-2017. Print 2017 Oct. No abstract available.

18.

Evidence-based interventions to reduce tuberculosis stigma: a systematic review.

Sommerland N, Wouters E, Mitchell EMH, Ngicho M, Redwood L, Masquillier C, van Hoorn R, van den Hof S, Van Rie A.

Int J Tuberc Lung Dis. 2017 Nov 1;21(11):81-86. doi: 10.5588/ijtld.16.0788. Review.

PMID:
29025489
19.

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.

20.

Association between genotype and drug resistance profiles of Mycobacterium tuberculosis strains circulating in China in a national drug resistance survey.

Zhou Y, van den Hof S, Wang S, Pang Y, Zhao B, Xia H, Anthony R, Ou X, Li Q, Zheng Y, Song Y, Zhao Y, van Soolingen D.

PLoS One. 2017 Mar 23;12(3):e0174197. doi: 10.1371/journal.pone.0174197. eCollection 2017.

21.

Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands.

de Vries G, van Hest R, Bakker M, Erkens C, van den Hof S, Meijer W, Oud K, Slump E, van Dissel J.

J Clin Tuberc Other Mycobact Dis. 2017 Mar 18;7:40-48. doi: 10.1016/j.jctube.2017.02.002. eCollection 2017 May.

22.

Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China.

Xia H, Zheng Y, Zhao B, van den Hof S, Cobelens F, Zhao Y.

PLoS One. 2017 Jan 12;12(1):e0169413. doi: 10.1371/journal.pone.0169413. eCollection 2017.

23.

Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting.

Van't Boveneind-Vrubleuskaya N, Daskapan A, Kosterink JG, van der Werf TS, van den Hof S, Alffenaar JC.

PLoS One. 2016 Nov 10;11(11):e0166030. doi: 10.1371/journal.pone.0166030. eCollection 2016.

24.

Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.

Erkens CG, Slump E, Verhagen M, Schimmel H, Cobelens F, van den Hof S.

Eur Respir J. 2016 Nov;48(5):1420-1428. doi: 10.1183/13993003.01157-2016. Epub 2016 Oct 6.

25.

The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.

van den Hof S, Collins D, Hafidz F, Beyene D, Tursynbayeva A, Tiemersma E.

BMC Infect Dis. 2016 Sep 5;16:470. doi: 10.1186/s12879-016-1802-x.

26.

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region.

Blok N, van den Boom M, Erkens C, Dara M, van den Hof S.

Eur Respir J. 2016 Sep;48(3):943-6. doi: 10.1183/13993003.00704-2016. Epub 2016 Jul 28. No abstract available.

27.

Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda.

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP, Horsburgh R, Lange C, Lienhardt C, Oren E, Podewils LJ, Seaworth B, van den Hof S, Daley CL, Gebhard AC, Wares F; RESIST-TB (Research Excellence to Stop TB Resistance) and GDI (Global Drug Resistant TB Initiative).

PLoS One. 2016 May 25;11(5):e0155968. doi: 10.1371/journal.pone.0155968. eCollection 2016. Review.

28.

Correction: Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial.

Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, Van den Hof S.

PLoS One. 2016 May 24;11(5):e0156471. doi: 10.1371/journal.pone.0156471. eCollection 2016.

29.

The Effects of Psycho-Emotional and Socio-Economic Support for Tuberculosis Patients on Treatment Adherence and Treatment Outcomes - A Systematic Review and Meta-Analysis.

van Hoorn R, Jaramillo E, Collins D, Gebhard A, van den Hof S.

PLoS One. 2016 Apr 28;11(4):e0154095. doi: 10.1371/journal.pone.0154095. eCollection 2016. Review.

30.

Cost-effectiveness of the Xpert® MTB/RIF assay for tuberculosis diagnosis in Brazil.

Pinto M, Steffen RE, Cobelens F, van den Hof S, Entringer A, Trajman A.

Int J Tuberc Lung Dis. 2016 May;20(5):611-8. doi: 10.5588/ijtld.15.0455.

PMID:
27084814
31.

Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.

Erkens CG, Slump E, Verhagen M, Schimmel H, de Vries G, Cobelens F, van den Hof S.

Eur Respir J. 2016 May;47(5):1492-501. doi: 10.1183/13993003.01397-2015. Epub 2016 Feb 25. Erratum in: Eur Respir J. 2017 Jan 25;49(1):.

32.

No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.

Cobelens F, Gebhard A, van den Hof S.

Int J Tuberc Lung Dis. 2016 Feb;20(2):282. doi: 10.5588/ijtld.15.0628. No abstract available.

PMID:
26792486
33.

Using existing data to illustrate--and close--the gap in access to new anti-tuberculosis drugs.

Mitnick C, van den Hof S.

Int J Tuberc Lung Dis. 2016 Feb;20(2):145. doi: 10.5588/ijtld.15.0911. No abstract available.

PMID:
26792461
34.

Elevated mortality after successful tuberculosis treatment.

van den Hof S, Borgdorff MW.

Int J Tuberc Lung Dis. 2016 Jan;20(1):2. doi: 10.5588/ijtld.15.0652. No abstract available.

35.

Correction: Impact of Replacing Smear Microscopy with Xpert MTB/RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized Trial.

Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, Menezes A, Cobelens F.

PLoS Med. 2015 Dec 3;12(12):e1001928. doi: 10.1371/journal.pmed.1001928. eCollection 2015 Dec. No abstract available.

36.

Correction: Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.

van Kampen SC, Tursynbayeva A, Koptleuova A, Murzakhmetova Z, Bigalieva L, Aubakirova M, Pak S, van den Hof S.

PLoS One. 2015 Aug 19;10(8):e0136368. doi: 10.1371/journal.pone.0136368. eCollection 2015. No abstract available.

37.

Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.

van Kampen SC, Tursynbayeva A, Koptleuova A, Murzakhmetova Z, Bigalieva L, Aubakirova M, Pak S, van den Hof S.

PLoS One. 2015 Jul 16;10(7):e0132514. doi: 10.1371/journal.pone.0132514. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0136368. Murzabekova, Zauresh [corrected to Murzakhmetova, Zauresh].

38.

How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?

Gebhard A, van den Hof S, Cobelens F.

Am J Respir Crit Care Med. 2015 Jul 1;192(1):117. doi: 10.1164/rccm.201503-0517LE. No abstract available.

PMID:
26131997
39.

Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.

Sachdeva KS, Raizada N, Sreenivas A, Van't Hoog AH, van den Hof S, Dewan PK, Thakur R, Gupta RS, Kulsange S, Vadera B, Babre A, Gray C, Parmar M, Ghedia M, Ramachandran R, Alavadi U, Arinaminpathy N, Denkinger C, Boehme C, Paramasivan CN.

PLoS One. 2015 May 21;10(5):e0126065. doi: 10.1371/journal.pone.0126065. eCollection 2015.

40.

Impact on Patients' Treatment Outcomes of XpertMTB/RIF Implementation for the Diagnosis of Tuberculosis: Follow-Up of a Stepped-Wedge Randomized Clinical Trial.

Trajman A, Durovni B, Saraceni V, Menezes A, Cordeiro-Santos M, Cobelens F, Van den Hof S.

PLoS One. 2015 Apr 27;10(4):e0123252. doi: 10.1371/journal.pone.0123252. eCollection 2015. Erratum in: PLoS One. 2016;11(5):e0156471.

41.

Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009.

van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS.

Int J Tuberc Lung Dis. 2015 Apr;19(4):406-12. doi: 10.5588/ijtld.14.0838.

PMID:
25859995
42.

HIV and multidrug-resistant tuberculosis: overlapping risk factors.

van den Hof S, Tursynbayeva A, Abildaev T, Adenov M, Pak S, Ismailov S.

Eur Respir J. 2015 Feb;45(2):567-9. doi: 10.1183/09031936.00131014. No abstract available.

43.

Impact of replacing smear microscopy with Xpert MTB/RIF for diagnosing tuberculosis in Brazil: a stepped-wedge cluster-randomized trial.

Durovni B, Saraceni V, van den Hof S, Trajman A, Cordeiro-Santos M, Cavalcante S, Menezes A, Cobelens F.

PLoS Med. 2014 Dec 9;11(12):e1001766. doi: 10.1371/journal.pmed.1001766. eCollection 2014 Dec. Erratum in: PLoS Med. 2015 Dec;12(12):e1001928.

44.

High positive predictive value of Xpert in a low rifampicin resistance prevalence setting.

Trajman A, Durovni B, Saraceni V, Cordeiro-Santos M, Cobelens F, van den Hof S.

Eur Respir J. 2014 Dec;44(6):1711-3. doi: 10.1183/09031936.00115514. Epub 2014 Sep 3. No abstract available.

45.

Operational lessons drawn from pilot implementation of Xpert MTB/Rif in Brazil.

Durovni B, Saraceni V, Cordeiro-Santos M, Cavalcante S, Soares E, Louren├žo C, Menezes A, van den Hof S, Cobelens F, Trajman A.

Bull World Health Organ. 2014 Aug 1;92(8):613-7. doi: 10.2471/BLT.13.131409. Epub 2014 May 1.

46.

The epidemiology of childhood tuberculosis in the Netherlands: still room for prevention.

Erkens CG, de Vries G, Keizer ST, Slump E, van den Hof S.

BMC Infect Dis. 2014 May 31;14:295. doi: 10.1186/1471-2334-14-295.

47.

Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands.

Erkens CG, Dinmohamed AG, Kamphorst M, Toumanian S, van Nispen-Dobrescu R, Alink M, Oudshoorn N, Mensen M, van den Hof S, Borgdorff M, Verver S.

Int J Tuberc Lung Dis. 2014 Apr;18(4):413-20. doi: 10.5588/ijtld.13.0589.

PMID:
24670695
48.

Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.

van den Hof S, Tursynbayeva A, Abildaev T, Adenov M, Pak S, Bekembayeva G, Ismailov S.

Int J Tuberc Lung Dis. 2013 Apr;17(4):526-31. doi: 10.5588/ijtld.12.0703.

PMID:
23485387
49.

Helminths and skewed cytokine profiles increase tuberculin skin test positivity in Warao Amerindians.

Verhagen LM, Hermans PW, Warris A, de Groot R, Maes M, Villalba JA, del Nogal B, van den Hof S, Mughini Gras L, van Soolingen D, Pinelli E, de Waard JH.

Tuberculosis (Edinb). 2012 Nov;92(6):505-12. doi: 10.1016/j.tube.2012.07.004. Epub 2012 Aug 9.

PMID:
22877977
50.

Measuring workload for tuberculosis service provision at primary care level: a methodology.

Blok L, van den Hof S, Mfinanga SG, Kahwa A, Ngadaya E, Oey L, Dieleman M.

Hum Resour Health. 2012 May 28;10:11. doi: 10.1186/1478-4491-10-11.

Supplemental Content

Loading ...
Support Center